Compare TG Therapeutics Inc (TGTX) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while Vanguard Total Stock Market Index Fund ETF trades at $381.95 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 281.9× TG Therapeutics Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is more actively traded (2,982,924 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| TGTX | VTI | |
|---|---|---|
Market Cap | $8.16B | $2.30T |
Volume | 1,735,121 | 2,982,924 |
Sector | Health | — |
52-Week High | $59.06 | $384.30 |
52-Week Low | $26.94 | $311.68 |
Typical Hold Time | 16 Days | 131 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
VTI trades at $381.94, up 0.24% on the day, with a bullish technical signal from moving averages. The ETF offers broad exposure to the U.S. stock market, though key valuation ratios like P/E and P/S are not provided in the current data. Recent news highlights its role in diversified portfolios and long-term growth potential, with a dividend scheduled for late September 2026.
The outlook for VTI is supported by its low-cost, diversified structure, appealing to long-term investors. Risks include market concentration in top holdings and overall equity market volatility. Analyst sentiment is generally positive, emphasizing its suitability for retirement and growth strategies amid current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
